ICER says bluebird bio’s $2.1m gene therapy is cost-effective
beta thalassaemia, bluebird bio, gene therapy, HEOR, ICER
0 Comment
beta thalassaemia
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Arbor Biotechnologies, beta thalassaemia, CRISPR/Cas9, gene editing, sickle cell disease, type 1 diabetes, Vertex Pharma
0 Comment
EMA finds possible link between mRNA COVID jabs and myocarditis
beta thalassaemia, bluebird bio, coronavirus, COVID-19, COVID-19 vaccine, ema, mRNA, PRAC, Rare diseases, Zynteglo
0 Comment
EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease
Acceleron, beta thalassaemia, Bristol-Myers Squibb, EHA 2021, luspatercept, myelodysplastic syndrome, Reblozyl
0 Comment
Zynteglo halt re-ignites viral vector safety concerns; analysts
beta thalassaemia, bluebird bio, cancer, gene therapy, lentivector, Oxford Biomedica, safety, Zynteglo
0 Comment
bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy
beta thalassaemia, bluebird bio, gene therapy, Haematology, NICE, Zynteglo
0 Comment
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
ASH, beta thalassaemia, bluebird bio, Haematology, Zinteglo
0 Comment
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disorders
beta thalassaemia, CRISPR Therapeutics, CRISPR/Cas9, gene editing, sickle cell disease, Vertex Pharma
0 Comment
1 2